talquetamab

Home
Ligands
talquetamab

GtoPdb Ligand ID: 12240

Synonyms: JNJ-64407564 | JNJ64407564 | talquetamab-tgvs | Talvey®

talquetamab is an approved drug (FDA & EMA (2023))

Comment: Talquetamab (JNJ-64407564) is a humanized, IgG4 bispecific monoclonal antibody that engages the orphan GPCR GPRC5D that's expressed on majority of malignant plasma cells from multiple myeloma (MM) patients and CD3ε on T cells [3]. It has amino acid substitutions in its Fc region to minimise binding to Fcγ receptors and antibody-directed effector functions. The peptide sequences for talquetamab's heavy and light chains are claimed in Janssen's patent US10562968B2 [1]. In preclinical studies talquetamab promoted immune killing of MM cells, including cells from patients with daratumumab-refractory disease [4].

References
1. Attar R, Gaudet F, Tornetta M, Teplyakov A, Mendonca M, Edavettal S, Pillarisetti K, Majewski N, Li Y, Luistro LL III et al.. (2020) Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof. Patent number: US10562968B2. Assignee: Janssen Pharmaceutica NV. Priority date: 20/07/2016. Publication date: 07/11/2022.
2. Keam SJ. (2023) Talquetamab: First Approval. Drugs, 83 (15): 1439-1445. [PMID:37792138]
3. Pillarisetti K, Edavettal S, Mendonça M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E et al.. (2020) A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood, 135 (15): 1232-1243. [PMID:32040549]
4. Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R et al.. (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv, 5 (8): 2196-2215. [PMID:33890981]

References

1. Attar R, Gaudet F, Tornetta M, Teplyakov A, Mendonca M, Edavettal S, Pillarisetti K, Majewski N, Li Y, Luistro LL III et al.. (2020)
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof.
Patent number: US10562968B2. Assignee: Janssen Pharmaceutica NV. Priority date: 20/07/2016. Publication date: 07/11/2022.

2. Keam SJ. (2023)
Talquetamab: First Approval.
Drugs, 83 (15): 1439-1445. [PMID:37792138]

3. Pillarisetti K, Edavettal S, Mendonça M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E et al.. (2020)
A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Blood, 135 (15): 1232-1243. [PMID:32040549]

4. Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R et al.. (2021)
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Blood Adv, 5 (8): 2196-2215. [PMID:33890981]